3D
...
MEI Pharma (NASDAQ: MEIP) has made history by acquiring 929,548 Litecoin (LTC) tokens at an average price of $107.58, launching a bold institutional treasury strategy now valued at approximately $110.4 million as of August 4, 2025. This move establishes MEI as the first publicly listed U.S. company to designate Litecoin as a primary reserve asset, signaling a new era of digital finance integration within corporate America.
Working closely with GSR and Litecoin creator Charlie Lee, who also serves on MEI’s Board, the company aims to leverage Litecoin’s strong track record, low transaction costs, and global adoption. Lee praised the move, calling it “a clear, institutional step” that acknowledges Litecoin’s role as both a sound store of value and an operational asset. Litecoin’s 13 years of uninterrupted uptime and integration into platforms like PayPal, Venmo, and Robinhood underscore its strength as a decentralized currency.
Looking ahead, MEI plans to expand this strategy with potential Litecoin mining operations and a refreshed corporate identity. The company also remains committed to advancing its pre-clinical pipeline, including research on its oral CDK9 inhibitor, voruciclib.
